PLoS ONE (Jan 2020)

Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.

  • Shigemune Bekki,
  • Satoru Hashimoto,
  • Kazumi Yamasaki,
  • Atsumasa Komori,
  • Seigo Abiru,
  • Shinya Nagaoka,
  • Akira Saeki,
  • Tomoyuki Suehiro,
  • Yuki Kugiyama,
  • Asami Beppu,
  • Tamotsu Kuroki,
  • Minoru Nakamura,
  • Masahiro Ito,
  • Hiroshi Yatsuhashi

DOI
https://doi.org/10.1371/journal.pone.0241002
Journal volume & issue
Vol. 15, no. 10
p. e0241002

Abstract

Read online

BackgroundWe examined serum kynurenine levels in patients with chronic hepatitis C virus infection, and the relationship between serum kynurenine and prognosis in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C.MethodsWe retrospectively analyzed 604 patients with HCC diagnosed between January 1999 and December 2015, and 288 patients without HCC who were seen at the National Hospital Organization Nagasaki Medical Center between October 2014 and November 2017. The association between serum kynurenine and prognosis was evaluated using the Cox's proportional hazards regression analysis.ResultsPatients with HCC had significantly higher values of serum kynurenine than patients without HCC (median: 557.1 vs. 464.2 ng/mL, pConclusionsA high level of serum kynurenine correlated with poor prognosis of HCC. Serum kynurenine levels may be a novel biomarker to predict the prognosis of patients with HCC. The development of drugs that inhibit kynurenine production is expected to help improve the prognosis of patients with HCC.